Integrated Diagnostics Holdings plc (IDHC.L)
ValueMarkers Composite Index
70% below intrinsic value ($0)
Integrated Diagnostics Holdings plc (IDHC.L) — VMCI valuation read
IDHC.L prints VMCI 62/100 inside the Healthcare sector, where the median sits at 50. The 12-point above-median delta is the cleanest single-number summary of Integrated Diagnostics Holdings plc's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On IDHC.L, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** IDHC.L trades at 24.0x earnings, 33% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 0.0x leaves covenant headroom; that is the risk line for Integrated Diagnostics Holdings plc on the trailing financials.
IDHC.L rose 0.5% over the trailing 7 days, with a -2.6% read on a 30-day basis.
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 2,000 diagnostic test services, including immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company operates in Egypt, Jordan, Sudan, and Nigeria. As of December 30, 2021, it operated a network of 452 branch labs. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.